Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSymphony Env. Regulatory News (SYM)

Share Price Information for Symphony Env. (SYM)

Share Price is delayed by 15 minutes
Get Live Data
6.75    0.00 (0.00%)
Bid:
6.00
Ask:
7.50
Spread: 1.50 (25.00%)
Market Cap: £15.95m
SYM Live PriceLast checked at - London Stock Exchange

Intraday Symphony Env. Share Chart

Pre-Close Trading Update

28 Apr 2026 07:00

RNS Number : 1040C
Symphony Environmental Tech. PLC
28 April 2026
 

 

 

This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

28 April 2026

 

Symphony Environmental Technologies plc

("Symphony", the "Company" or the "Group")

FY-2025 pre-close trading update and

 

Strong start to FY-2026 - first half profitability

 

Symphony Environmental Technologies plc ("Symphony" or the "Group"); global specialists in technologies that make plastic and rubber products "smarter, safer and sustainable", is pleased to provide the following pre-close trading update for the year ended 31 December 2025 ("FY-2025") and notice of FY-2025 results, together with a trading update for the current year to date.

FY2025 trading update (subject to audit)

Further to the Company's announcement on 17 December 2025, the Board now expects that, as a result of management‑driven strategic change in its Middle East operations, Group revenue for FY-2025 will be higher than previously guided, at approximately £5.7 million, with an adjusted loss before interest, tax, depreciation and amortisation ("adjusted LBITDA") broadly comparable to that incurred in the prior year, at approximately £0.9 million.

Importantly, and as further set out below, sales momentum has not just continued but accelerated during the first four months of FY-2026, running at more than 10 per cent. ahead of the same period last year. Furthermore, margins are also improving due to operational leverage as well as the positive impact of strategic initiatives taken during FY-2025, in particular in the Middle East.

In addition to the above adjusted LBITDA, the following one-off costs were incurred during FY-2025 as well as certain asset provisions will be made to the FY-2025 results:

· Strategic costs of £500,000 primarily in relation to the Middle East but also of certain future corporate initiatives;

· Impairment provision of £468,000 against development costs for the Group's antimicrobial products due to extended South American customer trials and commercial evaluation; and

· Other investment provisions of £107,000.

 

 

The net loss including provisions and strategic costs for FY-2025 is expected to be £2.5 million (FY-2024: £1.3 million).

The Board expects to announce its preliminary results for FY-2025 during the latter half of May.

Outlook

The Board remains focused on margin quality, disciplined cost control and the commercialisation of higher‑value technologies, rather than short‑term volume growth.

That said, it is particularly pleasing that trading in the first four months of 2026 has improved materially. The Group delivered a positive EBITDA in Q1-2026, compared with a loss in the corresponding prior‑year and based on current order patterns, expects to deliver a net profit for H1-2026.

Revenues are currently tracking more than 10 per cent ahead of the same period last year. Confirmed orders have been received across all principal markets, particularly Central America. While the timing of shipments remains subject to customer scheduling and customary operational factors, the Board is encouraged by the visibility and quality of the pipeline now in place, which underpins its confidence in the Group's earnings trajectory.

The Group continues to monitor the evolving geopolitical situation in the Middle East, which to date has not had a material adverse effect on operations.

Enquiries:

Symphony Environmental Technologies Plc

Michael Laurier, CEO

Tel: +44 (0) 20 8207 5900

Ian Bristow, CFO

www.symphonyenvironmental.com

Zeus (Nominated Adviser and Broker)

David Foreman, Emma Burn (Investment Banking)

Tel: +44 (0) 203 829 5000

NOTES TO EDITORS

 

 

About Symphony Environmental

 

 

Symphony's d2w masterbatch technology is added to polyethylene (PE) and polypropylene (PP) products at the manufacturing stage at little or no extra cost, and ensures that if they get into the environment at the end of their useful life they will not create microplastics and lie or float around for decades. https://www.symphonyenvironmental.com/technologies/biodegradable-plastic/ Instead they will safely biodegrade, leaving no microplastics or toxicity.

 

If they get collected during their programmed life they can be recycled with ordinary PE and PP without separation See https://www.biodeg.org/subjects-of-interest/recycling-2/

 

Symphony also supplies a range of plastic technologies under its d2p (designed to protect) brand www.d2p.net to provide protection against insects, viruses, bacteria, fungi, rodents, odours, and fire. 

 

It has also introduced a new product under its NbR brand https://www.symphonyenvironmental.com/natural-biodegradable-resin/ to reduce the amount of fossil-derived material in plastic products.

 

Symphony has a diverse and growing customer-base and has established itself as an international business with over 70 distributors around the world. Products made with Symphony's plastic technologies are now available in nearly 100 countries and in many different product applications. Symphony itself is certified according to ISO9001 and ISO14001.

 

Symphony participates in the Committee work of the British Standards Institute (BSI), the American Standards Organisation (ASTM), the European Standards Organisation (CEN), and the International Standards Organisation (ISO).

 

Further information on the Group can be found at www.symphonyenvironmental.com and twitter @SymphonyEnv

 

See also Symphony on Instagram and Linkedin.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFVDSAIDFIR
Date   Source Headline
16th Jul 20207:00 amRNSTrading & Market Update
8th Jul 20207:00 amRNSAppointment of Nominated Adviser and Joint Broker
26th Jun 20201:13 pmRNSResult of AGM & Update on Antiviral Testing
3rd Jun 20207:00 amRNSPosting of Annual Report & Accounts & AGM Notice
26th May 20207:00 amRNSPreliminary results
29th Apr 20204:40 pmRNSSecond Price Monitoring Extn
29th Apr 20204:35 pmRNSPrice Monitoring Extension
28th Apr 202012:14 pmRNSUpdate on preliminary results
6th Apr 20207:00 amRNSTrading and COVID-19 update
10th Mar 20209:15 amRNSReplacement: CGTN Global focuses on Symphony's d2p
10th Mar 20207:00 amRNSCGTN Global focuses on Symphony's d2p technology
3rd Mar 20204:41 pmRNSSecond Price Monitoring Extn
3rd Mar 20204:36 pmRNSPrice Monitoring Extension
3rd Mar 20202:00 pmRNSPrice Monitoring Extension
3rd Mar 202011:05 amRNSSecond Price Monitoring Extn
3rd Mar 202011:00 amRNSPrice Monitoring Extension
2nd Mar 20209:05 amRNSSecond Price Monitoring Extn
2nd Mar 20209:00 amRNSPrice Monitoring Extension
26th Feb 20207:00 amRNSFDA Approval for Antimicrobial Food Packaging
17th Dec 20197:00 amRNSTrading Update
20th Nov 20197:00 amRNSOption amendments and grant of options
8th Nov 20197:00 amRNSBoard Changes
8th Nov 20197:00 amRNSDirector/PDMR Shareholding
4th Nov 20197:00 amRNSDirector/PDMR Shareholding
11th Oct 201911:15 amRNSResult of General Meeting
11th Oct 20197:00 amRNSLSE - Green Economy Classification & Mark
27th Sep 20197:00 amRNSInterim Results
24th Sep 20197:00 amRNSNotice of GM
28th Aug 20197:00 amRNSAppointment of joint broker
22nd Aug 20197:00 amRNSGrupo Bimbo - d2w biodegradable packaging program
19th Jul 20199:23 amRNSEquity subscription and grant of warrants
14th May 20194:40 pmRNSSecond Price Monitoring Extn
14th May 20194:35 pmRNSPrice Monitoring Extension
10th May 20197:00 amRNSECHA update
3rd May 20192:52 pmRNSResult of AGM
3rd May 20197:00 amRNSAGM Statement
10th Apr 20197:00 amRNSPosting of Accounts and Notice of AGM
18th Mar 20193:18 pmRNSExercise of options and PDMR dealing
15th Mar 20197:00 amRNSPreliminary Results
17th Jan 201910:54 amRNSDirector/PDMR Shareholding
5th Nov 20187:00 amRNSJUDGE FINDS CASE FOR OXO-BIODEGRADABLE TECH PROVEN
16th Oct 20187:00 amRNSDirector/PDMR Shareholding - Extension of Options
12th Oct 20187:00 amRNSTrading Statement
25th Sep 20187:07 amRNSNew distributor launch held in Jordan
30th Aug 20187:00 amRNSInterim Results
6th Aug 20187:00 amRNSTrading & Operations Update
23rd Jul 20188:09 amRNSOxo-biodegradable technology statement
20th Jul 20181:10 pmRNSResponse to BBC Coverage
20th Jul 20189:05 amRNSSecond Price Monitoring Extn
20th Jul 20189:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.